Stay updated on Ipilimumab + Lymphodepletion + ACT + HD IL-2 Melanoma Mets Clinical Trial
Sign up to get notified when there's something new on the Ipilimumab + Lymphodepletion + ACT + HD IL-2 Melanoma Mets Clinical Trial page.

Latest updates to the Ipilimumab + Lymphodepletion + ACT + HD IL-2 Melanoma Mets Clinical Trial page
- ChecktodayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe webpage has been updated to include new information about the study on metastatic melanoma, specifically detailing the drugs and therapies involved, as well as the collaborators and study version. Notably, the previous details regarding the purpose and endpoints of the pilot study have been removed.SummaryDifference39%
- Check29 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and a date of February 10, 2025, has been added. However, the deletion of the date March 25, 2025, does not significantly impact core content.SummaryDifference0.3%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check80 days agoChange DetectedThe webpage has updated its date references, removing past dates from late 2024 and adding new dates in February 2025.SummaryDifference0.7%
Stay in the know with updates to Ipilimumab + Lymphodepletion + ACT + HD IL-2 Melanoma Mets Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ipilimumab + Lymphodepletion + ACT + HD IL-2 Melanoma Mets Clinical Trial page.